Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Yasuyuki Kawamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7706-0015; OpenAlex author ID A5026656732, A5132878642. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 15

  1. Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
  2. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  3. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  4. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  5. Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiother… Co-author DOI 10.1016/j.phro.2024.100690↗
  6. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  7. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  8. Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pa… Co-author DOI 10.3390/jcm12041596↗
  9. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  10. Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. First author DOI 10.1097/mpa.0000000000002028↗
  11. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan… First author DOI 10.1136/bmjopen-2021-048833↗
  12. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Co-author DOI 10.1002/onco.13838↗
  13. Comparison of FOLFIRINOX, Gemcitabine Plus Nab-Paclitaxel, and Chemoradiotherapy as First-Line Treatments for Locally Advanced Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-356113/v1↗
  14. Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000022250↗
  15. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Co-author DOI 10.21037/jgo.2017.02.02↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 6 shared papers, 2022–2025 · strength 0.90
  2. Naohiro Okano · 6 shared papers, 2022–2025 · strength 0.90
  3. Makoto Ueno · 6 shared papers, 2022–2025 · strength 0.90
  4. Chigusa Morizane · 6 shared papers, 2022–2025 · strength 0.90
  5. Kazuaki Harada · 6 shared papers, 2021–2026 · strength 0.81
  6. Yoshito Komatsu · 7 shared papers, 2017–2023 · strength 0.80
  7. Kumiko Umemoto · 5 shared papers, 2023–2025 · strength 0.79
  8. Shintaro Nakano · 6 shared papers, 2020–2023 · strength 0.74
  9. Naoya Sakamoto · 6 shared papers, 2017–2023 · strength 0.67
  10. Kunihiro Tsuji · 4 shared papers, 2022–2025 · strength 0.62
  11. Satoshi Kobayashi · 4 shared papers, 2022–2025 · strength 0.62
  12. Junji Furuse · 4 shared papers, 2022–2025 · strength 0.62
  13. Akinori Asagi · 4 shared papers, 2022–2025 · strength 0.59
  14. Takeshi Terashima · 3 shared papers, 2025 · strength 0.51
  15. Hiroshi Imaoka · 3 shared papers, 2025 · strength 0.51
  16. Rei Suzuki · 3 shared papers, 2022–2025 · strength 0.43
  17. Hiroaki Nagano · 3 shared papers, 2022–2025 · strength 0.43
  18. Nobumasa Mizuno · 3 shared papers, 2022–2024 · strength 0.39
  19. Masayuki Furukawa · 3 shared papers, 2022–2024 · strength 0.39
  20. Masaki Kuwatani · 3 shared papers, 2017–2026 · strength 0.36
  21. Kazumichi Kawakubo · 3 shared papers, 2017–2026 · strength 0.36
  22. Masato Ozaka · 2 shared papers, 2024–2025 · strength 0.34
  23. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  24. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  25. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.